Deciphera Pharmaceuticals, Inc.

NasdaqGS:DCPH Voorraadrapport

Marktkapitalisatie: US$2.2b

Deciphera Pharmaceuticals Beheer

Beheer criteriumcontroles 3/4

De CEO Deciphera Pharmaceuticals is Steve Hoerter, benoemd in Mar2019, heeft een ambtstermijn van 5.25 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 6.01M, bestaande uit 12.3% salaris en 87.7% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.084% van de aandelen van het bedrijf, ter waarde $ 1.86M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.3 jaar en 9 jaar.

Belangrijke informatie

Steve Hoerter

Algemeen directeur

US$6.0m

Totale compensatie

Percentage CEO-salaris12.3%
Dienstverband CEO5.3yrs
Eigendom CEO0.08%
Management gemiddelde ambtstermijn4.3yrs
Gemiddelde ambtstermijn bestuur9yrs

Recente managementupdates

Recent updates

Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) 61% Share Price Surge Not Quite Adding Up

Apr 30
Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) 61% Share Price Surge Not Quite Adding Up

Diving Into Deciphera Pharmaceuticals

Apr 26

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Mar 13
We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Dec 02
We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Are Investors Undervaluing Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) By 41%?

Sep 25
Are Investors Undervaluing Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) By 41%?

Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans

Jul 26
Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans

Calculating The Intrinsic Value Of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)

Jun 22
Calculating The Intrinsic Value Of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)

Lacklustre Performance Is Driving Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) Low P/S

May 08
Lacklustre Performance Is Driving Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) Low P/S

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Apr 10
We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Dec 29
We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Deciphera initiated at buy at Cowen on Qinlock growth, pipeline; sees 68% upside

Aug 29

Deciphera Pharmaceuticals Q2 2022 Earnings Preview

Aug 03

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Needs To Drive Business Growth Carefully

Jul 29
We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Needs To Drive Business Growth Carefully

Deciphera Pharmaceuticals: Not Too Happy With The Risk-Reward Right Now

Feb 11

Deciphera Pharmaceuticals: The 75% Haircut Doesn't Seem Justified

Nov 22

Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans

Aug 26
Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans

Deciphera Pharmaceuticals posts data from cancer studies at ASCO21

Jun 04

Companies Like Deciphera Pharmaceuticals (NASDAQ:DCPH) Are In A Position To Invest In Growth

May 10
Companies Like Deciphera Pharmaceuticals (NASDAQ:DCPH) Are In A Position To Invest In Growth

Analyse CEO-vergoeding

Hoe is Steve Hoerter's beloning veranderd ten opzichte van Deciphera Pharmaceuticals's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Mar 31 2024n/an/a

-US$190m

Dec 31 2023US$6mUS$738k

-US$195m

Sep 30 2023n/an/a

-US$194m

Jun 30 2023n/an/a

-US$187m

Mar 31 2023n/an/a

-US$182m

Dec 31 2022US$4mUS$703k

-US$179m

Sep 30 2022n/an/a

-US$221m

Jun 30 2022n/an/a

-US$258m

Mar 31 2022n/an/a

-US$286m

Dec 31 2021US$9mUS$676k

-US$300m

Sep 30 2021n/an/a

-US$274m

Jun 30 2021n/an/a

-US$258m

Mar 31 2021n/an/a

-US$255m

Dec 31 2020US$8mUS$650k

-US$266m

Sep 30 2020n/an/a

-US$271m

Jun 30 2020n/an/a

-US$263m

Mar 31 2020n/an/a

-US$218m

Dec 31 2019US$9mUS$435k

-US$192m

Sep 30 2019n/an/a

-US$157m

Jun 30 2019n/an/a

-US$126m

Mar 31 2019n/an/a

-US$126m

Dec 31 2018US$447kn/a

-US$100m

Compensatie versus markt: De totale vergoeding ($USD 6.01M ) Steve } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 5.54M ).

Compensatie versus inkomsten: De vergoeding van Steve is gestegen terwijl het bedrijf verliesgevend is.


CEO

Steve Hoerter (53 yo)

5.3yrs

Tenure

US$6,010,712

Compensatie

Mr. Steven L. Hoerter, also known as Steve, serves as Director at ORIC Pharmaceuticals, Inc. since August 2021. He has been President and Chief Executive Officer of Deciphera Pharmaceuticals, Inc. since Ma...


Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Steven Hoerter
President5.3yrsUS$6.01m0.084%
$ 1.9m
Thomas Kelly
Executive VP9.3yrsUS$2.03m0.049%
$ 1.1m
Dashyant Dhanak
Executive VP & Chief Scientific Officerless than a yearUS$3.06m0%
$ 0
Daniel Martin
Senior VP & Chief Commercial Officer5.8yrsUS$1.58m0.036%
$ 801.7k
Matthew Sherman
Executive VP & Chief Medical Officer4.7yrsUS$2.13m0.084%
$ 1.8m
Kevin Brodbeck
Senior VP & Chief Technical Officerless than a yeargeen gegevensgeen gegevens
Jennifer Larson
Senior Vice President of Finance & Investor Relationsno datageen gegevensgeen gegevens
Jeffrey Held
Senior VP & General Counsel5.3yrsgeen gegevensgeen gegevens
Lisa Price
Senior VP & Chief Human Resources Officer2.4yrsgeen gegevensgeen gegevens
Jama Pitman
Senior VP & Chief Development Officer4.3yrsgeen gegevens0.040%
$ 876.3k
Margarida Duarte
Senior VP & Head of International3.3yrsgeen gegevensgeen gegevens
Rodrigo Soto
Senior Vice President of Clinical Development3.4yrsgeen gegevensgeen gegevens

4.3yrs

Gemiddelde duur

53yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van DCPH wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.3 jaar).


Bestuursleden

NaamPositieTenureCompensatieEigendom
Steven Hoerter
President6.1yrsUS$6.01m0.084%
$ 1.9m
John Martin
Independent Director9.3yrsUS$388.59k0%
$ 0
Edward Benz
Independent Director7.7yrsUS$396.09k0%
$ 0
Patricia L. Allen
Independent Director7.8yrsUS$398.55k0%
$ 0
Ron Squarer
Independent Chairman4.5yrsUS$403.30k0%
$ 0
Jean-Yves Blay
Member of Scientific Advisory Board9yrsgeen gegevensgeen gegevens
James Bristol
Independent Director16.8yrsUS$414.77k0%
$ 0
John Condeelis
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Filip Janku
Member of Scientific Advisory Board9yrsgeen gegevensgeen gegevens
F. Hodi
Member of Scientific Advisory Board9yrsgeen gegevensgeen gegevens
Dennis Walsh
Independent Director9.3yrsUS$386.05k0.013%
$ 281.5k
John de Groot
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens

9.0yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van DCPH wordt beschouwd als ervaren (gemiddelde ambtstermijn 9 jaar).